Skip to main content

Nuvelo s Revenues Plunge, Losses Rise in Q1

NEW YORK, May 7 (GenomeWeb News) - Nuvelo yesterday reported increased losses and a drop in revenues for the first quarter of 2004.


Nuvelo's revenues plunged to $0.6 million, compared with $1.3 million in the first quarter of 2003. Net losses rose to $17.7 million, or $.65 per share, from year-ago losses of $13.6 million, or $.82 per share.


R&D expenses rose to $16.3 million in the quarter, compared with $10.8 million in the first quarter of 2003.


As of March 31, 2004, Nuvelo had $94 million in cash, cash equivalents, and short-term investments.


The Scan

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.